393 related articles for article (PubMed ID: 32605341)
1. [Analysis of clinical characteristics and drug treatment of inflammatory bowel disease in children: a single center study].
Zhang R; Zhong XM; Gong YZ; Ma X; Zhu D; Ning HJ; Wang FP; Zou JZ; Zhang YL
Zhonghua Er Ke Za Zhi; 2020 Jul; 58(7):570-575. PubMed ID: 32605341
[No Abstract] [Full Text] [Related]
2. Very-early-onset inflammatory bowel disease versus late-onset inflammatory bowel disease in relation to clinical phenotype: A cross-sectional study.
Mansour HH; Seddek SS; Meguid MEAEL; Eskander AE; Galal ST
Indian J Gastroenterol; 2023 Apr; 42(2):185-191. PubMed ID: 37166697
[TBL] [Abstract][Full Text] [Related]
3. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
4. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
5. Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease.
Kim ES; Choi S; Choe BH; Park S; Lee YJ; Sohn SJ; Kim SC; Kang KS; Lee K; Shim JO; Kim YB; Hong SJ; Lee YM; Kim HJ; Choi SY; Kim JY; Lee Y; Park JS; Kim JY; Yi DY; Lee JH; Choi KH; Jang HJ; Jeong IS; Kang B
Front Immunol; 2024; 15():1284181. PubMed ID: 38455036
[TBL] [Abstract][Full Text] [Related]
6. Variable outcome in infantile-onset inflammatory bowel disease in an Asian cohort.
Lee WS; Ng RT; Chan KW; Lau YL
World J Gastroenterol; 2016 Dec; 22(48):10653-10662. PubMed ID: 28082818
[TBL] [Abstract][Full Text] [Related]
7. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
[TBL] [Abstract][Full Text] [Related]
8. [The diagnostic and evaluation value of plasma interleukin 9 in the mucosal healing in patients with inflammatory bowel disease treated with biological agents].
Ye YL; Hu T; Xu LJ; Zhang LP; Yin J; Yu Q; Pang Z
Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1483-1489. PubMed ID: 37198111
[No Abstract] [Full Text] [Related]
9. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
Jongsma MME; Aardoom MA; Cozijnsen MA; van Pieterson M; de Meij T; Groeneweg M; Norbruis OF; Wolters VM; van Wering HM; Hojsak I; Kolho KL; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg-Roord STA; Schreurs MWJ; Rizopoulos D; Doukas M; Escher JC; Samsom JN; de Ridder L
Gut; 2022 Jan; 71(1):34-42. PubMed ID: 33384335
[TBL] [Abstract][Full Text] [Related]
10. [Single center retrospective study of 184 children with inflammatory bowel disease seen from 2000-2014].
Guan DX; Yu FH; Wang GL; Zhou J; Wang DY; Nie XL; Xu XW
Zhonghua Er Ke Za Zhi; 2017 Jul; 55(7):493-498. PubMed ID: 28728256
[No Abstract] [Full Text] [Related]
11. Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide.
Lazzerini M; Villanacci V; Pellegrin MC; Martelossi S; Magazzù G; Pellegrino S; Lucanto MC; Barabino A; Calvi A; Arrigo S; Lionetti P; Fontana M; Zuin G; Maggiore G; Bramuzzo M; Maschio M; Salemme M; Manenti S; Lorenzi L; Decorti G; Montico M; Ventura A
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1382-1389.e1. PubMed ID: 28286192
[TBL] [Abstract][Full Text] [Related]
12. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
[TBL] [Abstract][Full Text] [Related]
13. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
[TBL] [Abstract][Full Text] [Related]
14. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease.
Yang C; Singh P; Singh H; Le ML; El-Matary W
Aliment Pharmacol Ther; 2015 Jun; 41(11):1079-93. PubMed ID: 25858208
[TBL] [Abstract][Full Text] [Related]
15. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
[TBL] [Abstract][Full Text] [Related]
16. Spectrum and trend of pediatric inflammatory bowel disease: A two-decade experience from northern India.
Mohan N; Deswal S; Bhardwaj A
Indian J Gastroenterol; 2024 Feb; 43(1):208-214. PubMed ID: 37943479
[TBL] [Abstract][Full Text] [Related]
17. Current therapy of inflammatory bowel disease in children.
Rufo PA; Bousvaros A
Paediatr Drugs; 2006; 8(5):279-302. PubMed ID: 17037946
[TBL] [Abstract][Full Text] [Related]
18. Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy.
Gasparetto M; Guariso G; Pozza LV; Ross A; Heuschkel R; Zilbauer M
BMC Gastroenterol; 2016 Mar; 16():35. PubMed ID: 26976427
[TBL] [Abstract][Full Text] [Related]
19. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia.
Mokhtar NM; Nawawi KNM; Verasingam J; Zhiqin W; Sagap I; Azman ZAM; Mazlan L; Hamid HA; Yaacob NY; Rose IM; Den ELN; Wan MS; Raja Ali RA
BMC Public Health; 2019 Jun; 19(Suppl 4):550. PubMed ID: 31196184
[TBL] [Abstract][Full Text] [Related]
20. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
J Crohns Colitis; 2018 Nov; 12(11):1316-1325. PubMed ID: 30239644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
